Pfizer Patent for Cholesterol Drug Set to Expire Wednesday

Pfizer Inc.’s patent for the cholesterol drug Lipitor is set to expire Wednesday, New York Daily News reports.

Consequently, Lipitor, the nation’s best-selling drug [$11 billion a year for Pfizer], is about to get a lot cheaper. And while that may not be good news for Pfizer, it is good news for many patients struggling to pay for prescription drugs.

Bronx cashier Emily Flores had to stop taking Lipitor because her insurance no longer covered the medication. Last week, Flores drove to a lower-cost pharmacy in Westchester to fill her prescription but was shocked by the price when she got there. “They wanted $500 and change for a 90-day supply. I was devastated,” she told New York Daily News. “I told them, ‘I was expecting you to have a generic.’ He said, ‘Not yet.’”

Flores, 63, left the pharmacy empty-handed and went to talk with her doctor about taking an alternative drug.

“But now I might be able to afford it,” she told New York Daily News.

Dr. Robert Ostfeld, a cardiologist at Montefiore Medical Center in the Bronx, welcomes the expiration of the patent, which, he told New York Daily News, has kept prices too high for some of his patients.

“Generics are nearly, if not completely, identical to the non-generic version,” he told the newspaper. “It’s sad when patients have to legitimately choose between paying rent and taking a statin.” Two generics will be on the market for the first 180 days, and prices are expected to drop 10 percent in that time, New York Daily News reports. The rest of the generic equivalents will roll out in June and bring even deeper discounts. During the 180-day period, Pfizer hopes to retain customers by keeping retail costs down and offering a co-pay card that patients can use to lower a $50 co-pay to $4. The company is also trying a new low-cost mail-order service, deals with insurance companies to offer Lipitor at generic prices, and applying for over-the-counter status for Lipitor.
1 2 Next
Print Article